Roche puts pressure on SMA rivals with new FDA approval

[cafead]

via Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than two months of age.

article source